|
News
: LUMBY, BC Canada, Aug. 29 /PRNewswire-FirstCall/ -- avVaa World Health Care Products Inc. (OTC Bulletin Board: AVVW - News), a global biotechnology company offering therapeutic, natural skin and health care products announced today that it has placed the first of a series of full page, full color ads for its NeuroSkin line of skin products, in popular U.S. magazines with large North American audiences.
The first NeuroSkin advertisement for the Company's unique, steroid-free psoriasis and eczema relief product appeared in the August 7, 2006 issue of US Weekly magazine. US Weekly boasts nearly 5.5 million readers throughout the U.S. and Canada and is a popular source for headline and entertainment news around the world. A copy of the advertisement may be viewed online at: http://www.avvaa.com .
avVaa President and COO George Roadman, said, "We are excited to introduce this new line of print ads that are both informative and eye catching. Partnership with AdSouth ensures that NeuroSkin ads are placed directly in the hands of our target consumer market, conveying the benefits of our products to the individuals most likely to purchase them."
As a result of its recent collaboration to create print advertising with AdSouth Partners, additional avVaa advertisements will be published in First For Women, Parade, Prevention and other popular magazines with large readerships. The AdSouth Partners campaign for avVaa's NeuroSkin spray eczema/psoriasis Relief, targets consumers aged 18-65, as well as parents of children suffering with these conditions.
avVaa EVP of Sales and Marketing Lorie Campbell-Farley, said, "The facts are that 2.1% of the U.S. population suffers from psoriasis, and that means that 4.5 million adults in the U.S. have been diagnosed with this skin ailment with overall treatment costs exceeding $4 billion a year. NeuroSkin offers a superior, over the counter solution that provides relief for this ailment and other skin conditions.
"Prominent advertising allows us to introduce the product in trusted publications, and offers additional opportunities to grow our brand and market awareness in this ripe marketplace."
About NeuroSkin
AvVaa's proprietary NeuroSkin spray is an over the counter treatment that offers the promise of steroid-free, natural relief for common skin ailments. NeuroSkin is FDA compliant; using doctor recommended and tested nanotechnology that penetrates skin to provide cooling itch relief to a growing market of consumers who suffer with psoriasis, eczema and other skin ailments.
About avVaa World Health Care Products
avVaa World Health Care Products (AVVW) is a global biotechnology company that specializes in effective, all natural, therapeutic skin care products that improve quality of life and well being for consumers. avVaa's patented European skin care formulas are scientifically registered, FDA-Compliant, and were developed to relieve and treat the symptoms of common skin ailments, including: eczema, psoriasis and acne. avVaa is poised to manufacture and market its OTC Neuroskin line of skin care products through mass food and drug channels in the United States and globally. For more information, visit: http://www.avvaa.com or http://www.otcfn.com/avvw .
CONTACT:
Jack Farley CEO / President, at 1-866-772-8822 or visit: http://www.avvaa.com or http://www.otcfn.com/avvw
Investor Relations: Merle Goertz (West Coast) of avVaa World Health Care Products, 1-604-688-2349; or Rick McCaffrey of OTC Financial Network, 1-781-444-6100 ext. 625.
Safe Harbor: Statements contained in this press release that are not based upon current or historical fact are forward looking in nature. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from estimated results. Management cautions that all statements as to future results of operations are necessarily subject to risks, uncertainties, and events that may be beyond the control of AVVAA World Health Care Products, Inc. and no assurance can be given that such results will be achieved. Potential risks and uncertainties include but are not limited to the ability to procure, properly price, retain, and successfully complete projects, the availability of technical personnel, changes in technology, and competition.
|
